Delayed and Concurrent Stereotactic Radiosurgery in Immunotherapy-Naïve Melanoma Brain Metastases
Authors:
- Christine E. HadleyCHChristine E. Hadley
- Jennifer K. MatsuiJMJennifer K. Matsui
- Dukagjin M. BlakajDBDukagjin M. Blakaj
- Sasha BeyerSBSasha Beyer
- John C. GreculaJGJohn C. Grecula
- Arnab ChakravartiACArnab Chakravarti
- Evan ThomasETEvan Thomas
- Raju R. RavalRRRaju R. Raval
- James B. ElderJEJames B. Elder
- Kyle WuKWKyle Wu
- Kari KendraKKKari Kendra
- Pierre GiglioPierre Giglio
Open Access
Abstract
Melanoma remains a formidable challenge in oncology, causing the majority of skin cancer deaths in the United States, with brain metastases contributing substantially to this mortality. This paper reviews the current therapeutic strategies for melanoma brain metastases, with a focus on delayed and concurrent stereotactic radiosurgery (SRS). While surgery and traditional chemotherapy offer limited efficacy, recent advances in immunotherapy, particularly immune checkpoint inhibitors (ICIs), have played a major role in the advancement and improved efficacy of the treatment of cancers, including brain metastases. Recent studies indicate that monotherapy with ICIs may lead to a higher median overall survival compared to historical benchmarks, potentially allowing patients to delay radiosurgery. Other studies have found that combining SRS with ICIs demonstrates promise, with results indicating improved intracranial control. Ongoing clinical trials explore novel combinations of immunotherapies and radiotherapies, aiming to optimize treatment outcomes while minimizing adverse effects. As treatment options expand, future studies will be necessary to understand the interplay between therapies and their optimal sequencing to improve patient outcomes.Keywords
This publication has 70 references indexed in Scilit:
- Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysisClinical and Translational Radiation Oncology, 2023
- Stereotactic radiosurgery for melanoma brain metastases: dose-size response relationship in the era of immunotherapyJournal of Neuro-Oncology, 2021
- Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic MelanomaJAMA Oncology, 2020
- Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti–PD‐1 in patients with metastatic melanomaCancer, 2019
- The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta‐analysisCancer, 2019
- Clinical Management of Multiple Melanoma Brain MetastasesJAMA Oncology, 2015
- Radiation therapy for advanced and metastatic melanomaJournal of Surgical Oncology, 2013
- Metastatic melanomaCurrent Treatment Options in Oncology, 2001
- Cranial irradiation after surgical excision of brain metastases in melanoma patientsAnnals of Surgical Oncology, 1996
- Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2JAMA, 1994